Loading...
•
Jun 30, 2022
Zimmer Biomet Q2 2022 Earnings Report
Reported net sales increase of 1.0% and 6.0% on a constant currency basis and adjusted diluted earnings per share from continuing operations of $1.82.
Key Takeaways
Zimmer Biomet's Q2 2022 performance exceeded internal expectations due to a stronger COVID recovery and effective execution. Net sales reached $1.782 billion, a 1.0% increase, and adjusted diluted EPS was $1.82. The company updated its 2022 financial guidance, raising the full-year outlook.
Second quarter net sales from continuing operations of $1.782 billion increased 1.0% and 6.0% on a constant currency basis.
Second quarter diluted earnings per share from continuing operations were $0.73; adjusted diluted earnings per share from continuing operations were $1.82.
Company updates 2022 financial guidance, raising range for full year outlook
Launched new artificial intelligence (AI) capabilities within Omni™ Suite
Zimmer Biomet
Zimmer Biomet
Zimmer Biomet Revenue by Segment
Revenue by Segment
Knees Revenue
CapyFin.comHips Revenue
CapyFin.comS.E.T. Revenue
CapyFin.comTech/Data/Surgical Revenue
CapyFin.com Forward Guidance
The Company is updating its full-year 2022 financial guidance to raise its previous projected ranges for revenue growth, foreign currency exchange impact, adjusted operating profit margin and adjusted diluted EPS from continuing operations
Positive Outlook
- raising range for full year outlook
- 2022 Reported Revenue Change (1.0)% - 1.0%
- Adjusted Operating Profit Margin 26.75% - 27.75%
- Adjusted Tax Rate 16.0% - 16.5%
- Adjusted Diluted EPS from Continuing Operations $6.70 - $6.90
Challenges Ahead
- Foreign Currency Exchange Impact (5.0)%
Revenue & Expenses
Visualization of income flow from segment revenue to net income